Hims & Hers shares tumble
Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced ...
Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations ...
Hims & Hers Health reports its fourth-quarter results after Monday's closing bell. Here's a look at the key figures from the ...
Is Hims & Hers a millionaire-maker in the making? Yes! Or, at least, it can be. There is a possible future where Hims & Hers ...
Revenue excluding its GLP-1 offering increased 43% to $1.2 billion in 2024 from a year earlier, said Chief Financial Officer Yemi Okupe. Including sales of its weight-loss treatments, revenue surged ...
Hims&Hers Health Inc (NYSE:HIMS) reported weaker-than-expected fourth-quarter earnings that overshadowed the telehealth company's revenue that topped Wall Street estimates.
Shares of Hims & Hers Health ( HIMS -25.79%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost ...
Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...
Hims & Hers is expanding its offerings through the Trybe Labs deal after it added compounded weight loss drugs.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback